Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.7266
-0.0401-5.23%
Volume:2.71M
Turnover:2.05M
Market Cap:263.89M
PE:-1.43
High:0.7943
Open:0.7788
Low:0.7130
Close:0.7667
Loading ...

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

Reuters
·
28 Mar

BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851

Reuters
·
28 Mar

Lexicon Pharmaceuticals Shares up 70% Premarket on Licensing Deal With Novo Nordisk for Obesity Drug Candidate

THOMSON REUTERS
·
28 Mar

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

GlobeNewswire
·
28 Mar

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Simply Wall St.
·
27 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ) and Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
11 Mar

Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies

TIPRANKS
·
09 Mar

Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges

TIPRANKS
·
08 Mar

Lexicon Pharma Is Maintained at Overweight by Piper Sandler

Dow Jones
·
07 Mar

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire
·
07 Mar

Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

TIPRANKS
·
07 Mar

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
07 Mar

Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth

TIPRANKS
·
07 Mar

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
07 Mar

Lexicon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
07 Mar

Lexicon: Q4 Earnings Snapshot

Associated Press Finance
·
07 Mar

Lexicon Pharmaceuticals Q4 EPS $(0.09) Beats $(0.12) Estimate, Sales $26.55M Beat $6.48M Estimate

Benzinga
·
07 Mar

Lexicon Pharmaceuticals Q4 Operating Expenses USD 59.291 Million

THOMSON REUTERS
·
07 Mar

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
07 Mar